Page last updated: 2024-12-06

clinafloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

clinafloxacin: structure given in first source; RN given is for monoHCl [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60063
CHEMBL ID278255
CHEBI ID94459
SCHEMBL ID33959
MeSH IDM0160834

Synonyms (77)

Synonym
AB00647129-10
7-(3-amino-pyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
am-1091
bay-v-3545
pd-127391
clinafloxacin
7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-quinoline-3-carboxylic acid
am1091
105956-97-6
7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-8-chloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, monohydrochloride
ci-960
7-(3-amino-pyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
MLS000778572
smr000415366
3-quinolinecarboxylic acid, 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-
clinafloxacin [inn]
pd 127321
c17h17clfn3o3
HMS2090O15
7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
CHEMBL278255
7-(3-azaniumylpyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylate
STK802100
7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-quinoline-3-carboxylic acid;clinafloxacin
A801342
7-(3-azanylpyrrolidin-1-yl)-8-chloranyl-1-cyclopropyl-6-fluoranyl-4-oxidanylidene-quinoline-3-carboxylic acid
7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-3-quinolinecarboxylic acid
A801341
AKOS005622667
NCGC00246499-01
pd 127391
7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
am 1091
BBL010979
unii-8n86xtf9qd
8n86xtf9qd ,
S4006
BRD-A93964801-003-01-7
HMS2770F24
FT-0602938
clinafloxacin [mi]
clinafloxacin [who-dd]
3-quinolinecarboxylic acid, 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, (+/-)-
(+/-)-7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
CCG-220849
HY-B0536
SCHEMBL33959
QGPKADBNRMWEQR-UHFFFAOYSA-N
7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
clinafloxacin ci96 am1091
AC-32467
AB00647129_14
AB00647129_13
AB00647129_11
am 1091 (hydrochloride); ci 960 (hydrochloride);pd127391 (hydrochloride)
am-1091;ci-960;pd 127391
J-001508
mfcd00865120
sr-01000765993
SR-01000765993-2
clinafloxacin, vetranal(tm), analytical standard
CHEBI:94459
bdbm50474311
HMS3714J19
rkl10079
BCP21182
DTXSID80869455
Q3680752
clinafloxacin (hydrochloride)
7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-8-chloro-1,4-dihydro-4-oxo-3-quinolinecarboxylicacid
clinafloxacin (pd127391)
VS-02785
DB14025
AMY28813
gtpl10793
pd-127321

Research Excerpts

Overview

Clinafloxacin is a novel fluoroquinolone with a broad spectrum of antibacterial activity against both gramnegative and grampositive bacteria. It appears to be an appropriate agent for empirical treatment in febrile neutropenic cancer patients.

ExcerptReferenceRelevance
"Clinafloxacin is a potent intraphagocytic bactericidal agent for both gram-positive and gram-negative bacteria."( In vitro investigation of the intraphagocytic bioactivities of ciprofloxacin and the new fluoroquinolone agents, clinafloxacin (CI-960) and PD 131628.
Anderson, R; Jooné, GK,
)
1.06
"Clinafloxacin is a novel fluoroquinolone with a broad spectrum of antibacterial activity against both gramnegative and grampositive bacteria. "( Clinafloxacin (CL 960) is superior to standard therapeutics in the treatment of murine listeriosis and salmonellosis.
Bornitz, F; Hof, H; Kretschmar, M; Nichterlein, T, 1997
)
3.18
"Clinafloxacin is a novel quinolone with wide activity against the plethora of microorganisms encountered in intraabdominal infections. "( Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.
Bennion, RS; Christou, NV; Dellinger, EP; Pak, R; Rotstein, OD; Solomkin, JS; Tack, K; Wilson, SE, 2001
)
2.04
"Clinafloxacin is a new fluoroquinolone antibacterial with inhibitory activity against aerobic, anaerobic and atypical bacterial pathogens. "( Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data.
Frame, B; Koup, J; Lalonde, R; Miller, R, 2001
)
2.04
"Clinafloxacin (CI-960) is a potent broad-spectrum, fluoroquinolone antibiotic that has been studied for parenteral and oral administration in patients with serious infections. "( Pharmacokinetics of clinafloxacin after single and multiple doses.
Brodfuehrer, JI; Eiseman, I; Randinitis, EJ; Vassos, AB, 2001
)
2.08
"Clinafloxacin appears to be an appropriate agent for empirical treatment in febrile neutropenic cancer patients."( Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients.
Brennscheidt, U; Cornely, O; Figuera, A; Glauser, MP; Grigg, A; Keyserling, C; Tack, K; Trostmann, U; Welling, L, 2002
)
3.2

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Predicted toxicity data indicated that 27 molecules were less toxic or equivalent to that of the original drug (clinafloxacin)."( Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents.
Fan, L; Liu, J; Ren, Z; Tang, X; Wei, J; Xu, X; Yang, D, 2019
)
0.95

Pharmacokinetics

kg-1 dose of clinafloxacin in six rats, mean Cmax and AUC values increased in proportion to dose. ClinaflOxacin was rapidly absorbed, with Cmax occurring at approximately 40 min postdose.

ExcerptReferenceRelevance
" Clinafloxacin was rapidly absorbed, with Cmax occurring at approximately 40 min postdose."( The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.
Bron, NJ; Dorr, MB; Mant, TG; Vassos, AB; Webb, CL, 1996
)
1.48
" The objectives of this study are to evaluate the pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections and to describe our experience with mixed-effects modelling using heterogeneous pharmacokinetic data."( Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data.
Frame, B; Koup, J; Lalonde, R; Miller, R, 2001
)
0.83
" Plasma and urine samples were assayed by validated liquid chromatographic methods, and pharmacokinetic parameter values were determined by noncompartmental methods."( Pharmacokinetics of clinafloxacin after single and multiple doses.
Brodfuehrer, JI; Eiseman, I; Randinitis, EJ; Vassos, AB, 2001
)
0.63
"As the primary route for elimination of clinafloxacin is renal clearance (CL(R)) of unchanged drug, studies were conducted to determine the pharmacokinetic profile of clinafloxacin following administration to young and elderly subjects, subjects with various degrees of renal function, and subjects requiring dialysis."( Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.
Abel, R; Bron, NJ; Hounslow, NJ; Koup, JR; Randinitis, EJ; Rausch, G; Sedman, AJ; Vassos, AB, 2001
)
2.02
" The main pharmacokinetic parameters were obtained by 3P87 program."( [Pharmacokinetics and bioavailability of clinafloxacin in rats].
Cheng, WB; Duan, GL; Liu, X; Xu, CJ; Yu, YQ; Zhou, MH, 2001
)
0.58
"kg-1 dose of clinafloxacin in six rats, mean Cmax and AUC values increased in proportion to dose."( [Pharmacokinetics and bioavailability of clinafloxacin in rats].
Cheng, WB; Duan, GL; Liu, X; Xu, CJ; Yu, YQ; Zhou, MH, 2001
)
0.95
"The results of the pharmacokinetic study of clinafloxacin showed that it exhibited first order kinetic characteristics and the bioavailability is low."( [Pharmacokinetics and bioavailability of clinafloxacin in rats].
Cheng, WB; Duan, GL; Liu, X; Xu, CJ; Yu, YQ; Zhou, MH, 2001
)
0.84
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"The fluoroquinolones have been shown to interact with the hepatic metabolism of theophylline and increase serum theophylline concentrations."( Clinafloxacin-theophylline drug interaction.
Matuschka, PR; Vissing, RS, 1995
)
1.73
"Sparfloxacin and clinafloxacin alone and in combination with gentamicin, were evaluated for the treatment of experimental endocarditis in rabbits caused by ampicillin-resistant enterococci."( Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits.
Donabedian, SA; Perri, MB; Thal, LA; Vazquez, J; Zervos, MJ, 1993
)
0.97
"Many fluoroquinolone antibiotics are inhibitors of cytochrome P450 enzyme systems and may produce potentially important drug interactions when administered with other drugs."( Drug interactions with clinafloxacin.
Abel, R; Alvey, CW; Bron, NJ; Hounslow, NJ; Koup, JR; Randinitis, EJ; Rausch, G; Sedman, AJ; Vassos, AB, 2001
)
0.62
" The comet tail lengths of epidermal cells of the mice were statistically significantly increased for all three fluoroquinolones (FQ) tested in combination with UV irradiation."( Photo-chemically induced DNA effects in the comet assay with epidermal cells of SKH-1 mice after a single oral administration of different fluoroquinolones and 8-methoxypsoralen in combination with exposure to UVA.
Gross-Tholl, N; Herbold, B; von Keutz, E; Wirnitzer, U, 2006
)
0.33

Bioavailability

The results of the pharmacokinetic study of clinafloxacin showed that it exhibited first order kinetic characteristics and the bioavailability is low. The mean (+/- SD) bioavailability of R-clinafl Oxacin was 87%.

ExcerptReferenceRelevance
" The mean (+/- SD) bioavailability of R-clinafloxacin was 87."( Pharmacokinetics of clinafloxacin enantiomers in humans.
Brodfuehrer, JI; Guttendorf, RJ; Humphrey, GH; Randinitis, EJ; Shapiro, MA, 1999
)
0.89
" Absolute bioavailability of orally administered clinafloxacin was approximately 90% and did not change with increasing dose."( Pharmacokinetics of clinafloxacin after single and multiple doses.
Brodfuehrer, JI; Eiseman, I; Randinitis, EJ; Vassos, AB, 2001
)
0.89
"To study the pharmacokinetics and bioavailability of clinafloxacin in rats."( [Pharmacokinetics and bioavailability of clinafloxacin in rats].
Cheng, WB; Duan, GL; Liu, X; Xu, CJ; Yu, YQ; Zhou, MH, 2001
)
0.83
" The extent of bioavailability (F) of clinafloxacin was 42%."( [Pharmacokinetics and bioavailability of clinafloxacin in rats].
Cheng, WB; Duan, GL; Liu, X; Xu, CJ; Yu, YQ; Zhou, MH, 2001
)
0.85
"The results of the pharmacokinetic study of clinafloxacin showed that it exhibited first order kinetic characteristics and the bioavailability is low."( [Pharmacokinetics and bioavailability of clinafloxacin in rats].
Cheng, WB; Duan, GL; Liu, X; Xu, CJ; Yu, YQ; Zhou, MH, 2001
)
0.84
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
"62 mumol/L) and the theophylline dosage was increased to 300 mg tid."( Clinafloxacin-theophylline drug interaction.
Matuschka, PR; Vissing, RS, 1995
)
1.73
" In our patient, careful monitoring of theophylline concentrations and dosage adjustments resulted in the restoration of therapeutic serum concentrations."( Clinafloxacin-theophylline drug interaction.
Matuschka, PR; Vissing, RS, 1995
)
1.73
" Dosage adjustments may be warranted when this combination of medications is used."( Clinafloxacin-theophylline drug interaction.
Matuschka, PR; Vissing, RS, 1995
)
1.73
" Clinafloxacin at higher dosage (45 mg/kg/d) resulted in a decrease in myeloid progenitors in BM."( Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones.
Fabian, I; Gruss, T; Kletter, Y; Shalit, I; Weiss, K, 1997
)
1.21
" The same dosage regimen resulted in complete bacterial eradication in 88% of the kidneys."( Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model.
Desaty, TM; Griffin, TJ; Heifetz, CL; Sesnie, JC; Shapiro, MA, 1998
)
0.58
" pneumoniae, with standard dosing resulting in area under the concentration-time curve/MIC ratios and peak concentration/MIC ratios that resulted in 99."( Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Hershberger, E; Rybak, MJ, 2000
)
0.57
" Models were dosed the same as rabbit models, and SEVs were evaluated at the same time the rabbit vegetations were examined."( Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.
Coyle, EA; Hershberger, E; Kaatz, GW; Rybak, MJ; Zervos, MJ, 2000
)
0.31
" to oral dosing should achieve similar concentrations in plasma."( Pharmacokinetics of clinafloxacin after single and multiple doses.
Brodfuehrer, JI; Eiseman, I; Randinitis, EJ; Vassos, AB, 2001
)
0.63
" Animals were killed on Days 2, 3, 4, 5 or 8 (the dosing day was designated as Day 1), and the incidence of micronucleus in the epidermis was determined."( In vivo photochemical micronucleus induction due to certain quinolone antimicrobial agents in the skin of hairless mice.
Furuhama, K; Itoh, S; Katoh, M, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency6.91040.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency70.79460.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency125.89203.548119.542744.6684AID743266
DNA polymerase betaHomo sapiens (human)Potency31.62280.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency32.71530.133725.412989.1251AID588795; AID720498
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)0.06400.06008.9128130.5170AID1902
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA repair and recombination protein RAD54-like isoform 1Homo sapiens (human)AC5041.42000.814019.311978.9500AID651657
twin arginine protein translocation system - TatA proteinEscherichia coli str. K-12 substr. MG1655AC504.48600.707010.915145.8560AID504941
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (246)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID404299Antibacterial activity against Streptococcus pneumoniae type 3 infected in po dosed ICR mouse administered 1 hr after bacterial challenge measured at 7 days post infection2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID197877Antibacterial activity was determined against gram positive organism, Staphylococcus aureus H2281991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID78699Inhibition of Quinolone resistant gyrase Supercoiling Activity in Escherichia coli2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
AID404295Antibacterial activity against quinoline-resistant Staphylococcus aureus MS5935 containing double grlA and double gyrA mutation after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1510755Antibacterial activity against Pseudomonas aeruginosa ATCC 278532019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID1239965Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu(2+) mediated DNA-targeting antibacterial agents.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID64254Antibacterial activity was determined against gram negative organism, E. coli(vogel)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1239961Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu(2+) mediated DNA-targeting antibacterial agents.
AID1557282Antibacterial activity against Bacteroides fragilis by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID404282Toxicity in ICR mouse assessed as mortality administered as single dose at 100 mg/kg, iv after 7 days2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID203174In vitro inhibitory activity against Serratia marcescens1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID198176Antibacterial activity was determined against gram positive organism, Streptococcus pneumoniae SV-11991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID404283Toxicity in ICR mouse assessed as mortality administered as single dose at 200 mg/kg, iv after 7 days2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID74723MIC ratio measured as the mean MICs of gram-negative bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID74734MIC ratio measured as the mean MICs of gram-positive bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID163740In vitro antibacterial activity was tested for Providencia rettgeri H17711995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID1239962Antibacterial activity against Salmonella enterica ATCC 14028 after 24 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu(2+) mediated DNA-targeting antibacterial agents.
AID50549In vitro inhibitory activity against Citrobacter freundii1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID1557283Antibacterial activity against Haemophilus influenzae with horse blood by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1557281Antibacterial activity against Klebsiella by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1557037Antibacterial activity against methicillin-resistant Staphylococcus aureus N315 incubated for 24 hrs by two fold serial dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Indole-nitroimidazole conjugates as efficient manipulators to decrease the genes expression of methicillin-resistant Staphylococcus aureus.
AID1126759Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 821 assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID675301Antibacterial activity against methicillin-resistant Staphylococcus aureus N 315 by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
AID151052Antibacterial activity was determined against gram negative organism, Pseudomonas aeruginosa UI-181991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID68339In vitro antibacterial activity was tested for Enterobacter cloacae HA26461995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID151374Antibacterial activity was determined against gram negative organism, Providencia rettgeri. M17711991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID207830Minimum inhibitory concentration against Staphylococcus aureus - methicillin resistant Ciprofloxacin resistant, strain MI3392003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
AID404273Antibacterial activity against Staphylococcus aureus Smith after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1126757Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 758 assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID404293Antibacterial activity against quinoline-resistant Staphylococcus aureus MS5935 containing single grlA and single gyrA mutation after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID404297Antibacterial activity against Staphylococcus aureus Smith infected in po dosed ICR mouse administered 1 hr after bacterial challenge measured at 7 days post infection2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID404291Antibacterial activity against quinoline-resistant wild type Staphylococcus aureus MS5935 after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1220557Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID117691The in vivo potency was determined in female charles river CD-1 mice infected with Streptococcus pyogenes after peroral administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID74727Antibacterial activity against five Gram-negative bacteria1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID1557288Antibacterial activity against Clostridium perfringens by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID94123Antibacterial activity was determined against gram negative organism, K. pneumoniae (MGH-2)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1557284Antibacterial activity against Staphylococcus aureus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID117690The in vivo potency was determined in female charles river CD-1 mice infected with Streptococcus pneumoniae after sc administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1126751Antibacterial activity against Staphylococcus aureus assessed as zone of inhibition at 2 ug/ml2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1220560Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1574092Antibacterial activity against Salmonella S1.1152 assessed as diameter of zone of inhibition at 80 ug/ml after 18 hrs by agar diffusion method2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents.
AID404288Inhibition of quinoline-resistant Staphylococcus aureus MS5935 DNA gyrase-mediated supercoiling activity2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1126752Antibacterial activity against Escherichia coli assessed as zone of inhibition at 2 ug/ml2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1557280Antibacterial activity against Pseudomonas aeruginosa by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID404292Antibacterial activity against quinoline-resistant Staphylococcus aureus MS5935 containing single grlA mutation after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID66388In vitro inhibitory activity against Enterobacteriaceae; Range is 0.016-0.5 ug/mL1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID198317Antibacterial activity was determined against gram positive organism, Streptococcus pyogenes C2031991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID200231Antibacterial activity was determined against gram positive organism, Staphylococcus aureus (UC76)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID68676In vitro antibacterial activity was tested for Escherichia coli Vogel1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID1557308AUC in human at 0.2 g, po bid2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1220559Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1220558Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID230838MIC ratio measured as the mean MICs of gram-negative bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID521816Antimicrobial activity against Prevotella intermedia isolated from canine periodontal pockets after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Activity of pradofloxacin against Porphyromonas and Prevotella spp. Implicated in periodontal disease in dogs: susceptibility test data from a European multicenter study.
AID208121In vitro antibacterial activity was tested for Streptococcus pneumoniae SV-11995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID675305Antibacterial activity against Escherichia coli JM109 by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
AID1281665Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by micro broth dilution method2016European journal of medicinal chemistry, Mar-23, Volume: 111Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID404284Toxicity in intracerebroventricularly dosed ICR mouse assessed as induction of convulsion after 2 hrs in absence of fenbufen2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID78700Inhibition of Wild Type DNA gyrase Supercoiling Activity in Escherichia coli2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
AID206086In vitro inhibitory activity against Streptococci; Range is 0.06-0.25 ug/mL1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID1557042Antibacterial activity against Pseudomonas aeruginosa incubated for 24 hrs by two fold serial dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Indole-nitroimidazole conjugates as efficient manipulators to decrease the genes expression of methicillin-resistant Staphylococcus aureus.
AID230840MIC ratio measured as the mean MICs of gram-positive bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID404274Antibacterial activity against Haemophilus influenzae IID983 after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1574093Antibacterial activity against Salmonella S1.1152 measured after 120 days of sample dissolution by serial dilution method2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents.
AID1281666Antibacterial activity against Bacillus proteus ATCC 13315 by micro broth dilution method2016European journal of medicinal chemistry, Mar-23, Volume: 111Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.
AID1239959Antibacterial activity against Escherichia coli JM109 after 24 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu(2+) mediated DNA-targeting antibacterial agents.
AID1510732Antibacterial activity against Enterococcus faecalis2019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID207831Minimum inhibitory concentration against Staphylococcus aureus - methicillin resistant Ciprofloxacin sensitive strain MI3002003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
AID1557287Antibacterial activity against Enterococcus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID675307Antibacterial activity against Pseudomonas aeruginosa by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
AID1889622Antibacterial activity against Staphylococcus aureus 25923 assessed as inhibition of bacterial growth by two fold serial dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID675309Antifungal activity against Candida albicans ATCC 76615 by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
AID1126764Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1288 assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID404277Antibacterial activity against quinoline-resistant Staphylococcus aureus OITI MR1-1002 isolate after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1510754Antibacterial activity against methicillin-resistant Staphylococcus aureus N3152019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID96407In vitro antibacterial activity was tested for Klebsiella pneumoniae MGH-21995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID198316Antibacterial activity was determined against gram positive organism, Streptococcus pyogenes (C203)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID198174Antibacterial activity was determined against gram positive organism, Streptococcus pneumoniae (SV-1)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID64404The in vivo potency was determined in female charles river CD-1 mice infected with Escherichia coli after peroral administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1557043Antibacterial activity against Acinetobacter baumannii incubated for 24 hrs by two fold serial dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Indole-nitroimidazole conjugates as efficient manipulators to decrease the genes expression of methicillin-resistant Staphylococcus aureus.
AID1574096Antibacterial activity against duck Escherichia coli clinical isolates assessed as diameter of zone of inhibition at 80 ug/ml after 18 hrs by agar diffusion method2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents.
AID117692The in vivo potency was determined in female charles river CD-1 mice infected with Streptococcus pyogenes after sc administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1281660Antibacterial activity against Staphylococcus aureus ATCC 25923 by micro broth dilution method2016European journal of medicinal chemistry, Mar-23, Volume: 111Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.
AID1510758Antibacterial activity against Klebsiella pneumoniae2019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID197882Antibacterial activity was determined against gram positive organism, Staphylococcus aureus UC761991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID404272Antibacterial activity against Streptococcus pyogenes IID692 after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1557285Antibacterial activity against Streptococcus pneumoniae by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1239966Antibacterial activity against Micrococcus luteus ATCC 4698 after 24 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu(2+) mediated DNA-targeting antibacterial agents.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID50848In vitro antibacterial activity was tested for Clostridium diff CD1-11995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID758162Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by twofold broth dilution method2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and bioactive evaluation of novel hybrids of metronidazole and berberine as new type of antimicrobial agents and their transportation behavior by human serum albumin.
AID404294Antibacterial activity against quinoline-resistant Staphylococcus aureus MS5935 containing double grlA and single gyrA mutation after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1239960Antibacterial activity against Bacillus proteus ATCC 13315 after 24 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu(2+) mediated DNA-targeting antibacterial agents.
AID675303Antibacterial activity against Bacillus subtilis ATCC 6633 by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
AID117862Phototoxic skin reaction in depilated female CD-1 mice1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID57388Minimum inhibitory concentration against Escherichia coli DNA-gyrase in supercoiling assay1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID162936Minimum inhibitory concentration against Pseudomonas aeruginosa, strain PS962003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
AID1889625Antibacterial activity against Escherichia coli assessed as inhibition of bacterial growth by two fold serial dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID1126762Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1256 assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1889627Antibacterial activity against Pseudomonas aeruginosa assessed as inhibition of bacterial growth by two fold serial dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID675306Antibacterial activity against Shigella dysenteriae by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
AID41263In vitro antibacterial activity against Bacteroides fragilis BFA1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID675310Antifungal activity against Candida mycoderma by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
AID1281661Antibacterial activity against Micrococcus luteus ATCC 4698 by micro broth dilution method2016European journal of medicinal chemistry, Mar-23, Volume: 111Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1889628Antibacterial activity against Pseudomonas aeruginosa 27853 assessed as inhibition of bacterial growth by two fold serial dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID1126746Antibacterial activity against Staphylococcus aureus assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID94001Antibacterial activity was determined against gram negative organism, Klebsiella pneumoniae MGH-21991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1126754Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID200230Antibacterial activity was determined against gram positive organism, Staphylococcus aureus (H228)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1889624Antibacterial activity against Klebsiella pneumoniae assessed as inhibition of bacterial growth by two fold serial dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID1125568Antimalarial activity against blood stage form of Plasmodium falciparum assessed as incorporation of [3H]hypoxanthine after 72 hrs by liquid scintillation counting2014European journal of medicinal chemistry, Apr-22, Volume: 77Emergence of pyrido quinoxalines as new family of antimalarial agents.
AID1889619Antibacterial activity against methicillin-resistant Staphylococcus aureus N315 assessed as inhibition of bacterial growth by two fold serial dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID1281663Antibacterial activity against Escherichia coli DH52 by micro broth dilution method2016European journal of medicinal chemistry, Mar-23, Volume: 111Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.
AID117689The in vivo potency was determined in female charles river CD-1 mice infected with Streptococcus pneumoniae after peroral administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1889620Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth by two fold serial dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID404270Antibacterial activity against Escherichia coli NIHJ JC2 after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1510752Antibacterial activity against Staphylococcus aureus ATCC 259232019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID404298Antibacterial activity against Streptococcus pneumoniae type 3 infected in subcutaneously dosed ICR mouse administered 1 hr after bacterial challenge measured at 7 days post infection2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID67912In vitro inhibitory activity against Enterococcus faecalis1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID206764In vitro antibacterial activity was tested for Staphylococcus aureus H2281995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID1889629Antibacterial activity against Acinetobacter baumannii assessed as inhibition of bacterial growth by two fold serial dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID198021Antibacterial activity was determined against gram positive organism, Streptococcus faecalis MGH-21991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID208293Minimum inhibitory concentration against Streptococcus pneumoniae - penicillin resistant, strain STP512003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
AID1557327Phototoxicity in human2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID63899Antibacterial activity against gram negative organism, Escherichia cloacae (MA2646)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID324746Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID50999In vitro antibacterial activity against Clostridium perfringens CP 3-11995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID209232In vitro antibacterial activity was tested for Streptococcus faecalis MGH-21995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID404281Antibacterial activity against vancomycin-resistant Enterococcus faecalis KU1866 after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1239964Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu(2+) mediated DNA-targeting antibacterial agents.
AID206765In vitro antibacterial activity was tested for Staphylococcus aureus UC-761995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID1126755Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 741 assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID404269Antibacterial activity against Klebsiella pneumoniae IID5209 after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1557041Antibacterial activity against Escherichia coli incubated for 24 hrs by two fold serial dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Indole-nitroimidazole conjugates as efficient manipulators to decrease the genes expression of methicillin-resistant Staphylococcus aureus.
AID1126756Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 753 assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1281664Antibacterial activity against Escherichia coli JM109 by micro broth dilution method2016European journal of medicinal chemistry, Mar-23, Volume: 111Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.
AID69639Minimum inhibitory concentration against Escherichia coli2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Artificial neural network applied to prediction of fluorquinolone antibacterial activity by topological methods.
AID404275Antibacterial activity against Streptococcus pneumoniae type 3 after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1574090Antibacterial activity against Pseudomonas aeruginosa PS1.0050 assessed as diameter of zone of inhibition at 80 ug/ml after 18 hrs by agar diffusion method2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents.
AID404296Antibacterial activity against Staphylococcus aureus Smith infected in subcutaneously dosed ICR mouse administered 1 hr after bacterial challenge measured at 7 days post infection2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1220555Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID64251Antibacterial activity was determined against gram negative organism, Escherichia coli vogel1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID404290Inhibition of quinoline-resistant Staphylococcus aureus MS5935 topoisomerase 4-mediated decatenation activity2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1281658Antibacterial activity against Shigella dysenteriae by micro broth dilution method2016European journal of medicinal chemistry, Mar-23, Volume: 111Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.
AID1557279Antibacterial activity against Escherichia coli by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1510726Antibacterial activity against Escherichia coli2019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID1510753Antibacterial activity against Staphylococcus aureus ATCC 292132019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID64580Minimum inhibitory concentration against Escherichia coli, strain ES1422003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID675304Antibacterial activity against Micrococcus luteus ATCC 4698 by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
AID675308Antibacterial activity against Bacillus proteus by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
AID165206In vitro antibacterial activity was tested for Pseudomonas aeruginosa UI-181995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID1126745Antibacterial activity against Pseudomonas aeruginosa assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1557040Antibacterial activity against Klebsiella pneumoniae incubated for 24 hrs by two fold serial dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Indole-nitroimidazole conjugates as efficient manipulators to decrease the genes expression of methicillin-resistant Staphylococcus aureus.
AID1126747Antibacterial activity against Escherichia coli assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1126744Antibacterial activity against Salmonella assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1510757Antibacterial activity against Escherichia coli ATCC 259222019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID404289Inhibition of Staphylococcus aureus MS5935 wild type topoisomerase 4-mediated decatenation activity2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID64405The in vivo potency was determined in female charles river CD-1 mice infected with Escherichia coli after sc administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1126761Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1237 assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1574091Antibacterial activity against Pseudomonas aeruginosa PS1.0050 measured after 120 days of sample dissolution by serial dilution method2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents.
AID160372In vitro antibacterial activity was tested for Propion acnes PA5-11995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID1239963Antibacterial activity against methicillin-resistant Staphylococcus aureus N315 after 24 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu(2+) mediated DNA-targeting antibacterial agents.
AID1126748Antibacterial activity against duck Escherichia coli assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1126763Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1259 assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1557039Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 24 hrs by two fold serial dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Indole-nitroimidazole conjugates as efficient manipulators to decrease the genes expression of methicillin-resistant Staphylococcus aureus.
AID51918Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID1574097Antibacterial activity against duck Escherichia coli clinical isolates measured after 120 days of sample dissolution by serial dilution method2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents.
AID1574094Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as diameter of zone of inhibition at 80 ug/ml after 18 hrs by agar diffusion method2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents.
AID68675In vitro antibacterial activity was tested for Escherichia coli H5601995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID404280Antibacterial activity against vancomycin-resistant Enterococcus faecalis KU1856 after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID324754Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing after 9 months2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID1889626Antibacterial activity against Escherichia coli 25922 assessed as inhibition of bacterial growth by two fold serial dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID1557309Half life in human at 0.2 g, po bid2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID157244In vitro antibacterial activity was tested for Pepto asac PA 3-11995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID213599Clonogenic cytotoxicity against Chinese hamster V-79 cells1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID1281659Antibacterial activity against methicillin-resistant Staphylococcus aureus N315 by micro broth dilution method2016European journal of medicinal chemistry, Mar-23, Volume: 111Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.
AID1510756Antibacterial activity against Acinetobacter baumannii2019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID404279Antibacterial activity against quinoline-resistant Enterococcus faecalis No.15 isolate after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1281667Antibacterial activity against Salmonella enterica ATCC 14028 by micro broth dilution method2016European journal of medicinal chemistry, Mar-23, Volume: 111Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.
AID1126760Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 930 assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID208294Minimum inhibitory concentration against Streptococcus pneumoniae - penicillin sensitive, strain STP642003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
AID1126758Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 760 assessed as growth inhibition after 7 days by microtiter plate assay2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID150908Antibacterial activity was determined against gram negative organism, Pseudomonas aeruginosa (UI-18)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID63898Antibacterial activity was determined against gram negative organism, Enterobacter cloacae MA26461991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID198020Antibacterial activity was determined against gram positive organism, Streptococcus faecalis (MGH-2)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID74853Antibacterial activity against five Gram-positive bacteria targeting topoisomerase II (DNA gyrase B GyrB)1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID209612In vitro antibacterial activity was tested for Streptococcus pyogenes C2031995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID163730In vitro inhibitory activity against Providencia species1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID1126753Antibacterial activity against duck Escherichia coli assessed as zone of inhibition at 2 ug/ml2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID404276Antibacterial activity against Pseudomonas aeruginosa IID1210 after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID404278Antibacterial activity against quinoline-resistant Streptococcus pneumoniae no.55 isolate after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID324745Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID1281662Antibacterial activity against Bacillus subtilis ATCC 6633 by micro broth dilution method2016European journal of medicinal chemistry, Mar-23, Volume: 111Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1889621Antibacterial activity against Staphylococcus aureus assessed as inhibition of bacterial growth by two fold serial dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID1574095Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 120 days of sample dissolution by serial dilution method2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents.
AID1126749Antibacterial activity against Salmonella assessed as zone of inhibition at 2 ug/ml2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID206784In vitro inhibitory activity against ciprofloxacin resistant MRSA1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
New directions in antibacterial research.
AID1889623Antibacterial activity against Staphylococcus aureus 29213 assessed as inhibition of bacterial growth by two fold serial dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID675302Antibacterial activity against Staphylococcus aureus ATCC 25293 by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1126750Antibacterial activity against Pseudomonas aeruginosa assessed as zone of inhibition at 2 ug/ml2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1557286Antibacterial activity against Streptococcus pyogenes by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID404286Phototoxicity in orally dosed ICR mouse assessed as skin erythema after 72 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID118113Phototoxic skin reaction in depilated female CD-1 mice1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1220556Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1557310Protein binding in human at 0.2 g, po bid2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID151373Antibacterial activity was determined against gram negative organism, Providencia rettgeri. (M1771)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID404287Inhibition of Staphylococcus aureus MS5935 wild type DNA gyrase-mediated supercoiling activity2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1557038Antibacterial activity against Enterococcus faecalis incubated for 24 hrs by two fold serial dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Indole-nitroimidazole conjugates as efficient manipulators to decrease the genes expression of methicillin-resistant Staphylococcus aureus.
AID404285Toxicity in intracerebroventricularly dosed ICR mouse assessed as induction of convulsion after 2 hrs in presence of fenbufen2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1510727Antibacterial activity against Pseudomonas aeruginosa2019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID521824Antimicrobial activity against Porphyromonas isolated from canine periodontal pockets after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Activity of pradofloxacin against Porphyromonas and Prevotella spp. Implicated in periodontal disease in dogs: susceptibility test data from a European multicenter study.
AID324747Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID404271Antibacterial activity against Enterococcus faecalis IID682 after 18 hrs by agar dilution method2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
AID1557307Cmax in human at 0.2 g, po bid2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID54107Minimum inhibitory concentration required to inhibit DNA gyrase supercoiling.1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1220554Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (172)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (2.91)18.7374
1990's89 (51.74)18.2507
2000's51 (29.65)29.6817
2010's24 (13.95)24.3611
2020's3 (1.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.66 (24.57)
Research Supply Index5.30 (2.92)
Research Growth Index5.91 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (8.74%)5.53%
Reviews6 (3.28%)6.00%
Case Studies4 (2.19%)4.05%
Observational0 (0.00%)0.25%
Other157 (85.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]